Skip to main
SPTX

SPTX Stock Forecast & Price Target

SPTX Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Seaport Therapeutics is poised for success as their GlyphAllo and GlyphAgo drugs have shown promise in Phase 1 trials and have the potential to serve a growing market in need of more effective and safer treatments for mental health disorders. With top-line data expected in 1H27 and 2028 respectively, investors can expect potential revenue growth from these drugs and their differentiated lymphatic-targeting prodrug technology. Additionally, Seaport's diversified pipeline and strong management team make them an attractive target for potential M&A interest, further adding to their growth potential.

Bears say

Seaport Therapeutics is a clinical-stage therapeutics company with a pipeline of neuropsychiatric drugs that utilize lymphatic-targeting technology. While the company's collaboration with PureTech Health and recent Series A financing may suggest promise, its competitors and uncertain market acceptance pose significant risks for future profitability. Additionally, the company's lack of current revenue and uncertain cash flow projections make it a risky investment in the near-term.

SPTX has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Seaport Therapeutics Inc (SPTX) Forecast

Analysts have given SPTX a Strong Buy based on their latest research and market trends.

According to 7 analysts, SPTX has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Seaport Therapeutics Inc (SPTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.